Bioequivalence Study of Two Oral Formulations of Irbesartan 300 mg in Healthy Volunteers

M. Cánovas; F. Cabré; F. Polonio

doi:10.1055/s-0033-1353172

Drug Research, Table of Contents

Drug Res (Stuttg) 2014; 64(01): 53-56
DOI: 10.1055/s-0033-1353172

Original Article

Bioequivalence Study of Two Oral Formulations of Irbesartan 300 mg in Healthy Volunteers

Authors

M. Cánovas

¹Laboratorios Lesvi, S. L. - Invent Farma Group, Sant Joan Despí, Barcelona, Spain
F. Cabré

¹Laboratorios Lesvi, S. L. - Invent Farma Group, Sant Joan Despí, Barcelona, Spain
F. Polonio

¹Laboratorios Lesvi, S. L. - Invent Farma Group, Sant Joan Despí, Barcelona, Spain

Abstract

A bioequivalence study of 2 irbesartan (CAS 138402-11-6) film-coated tablet formulations was carried out in 40 healthy volunteers according to an open label, randomized, 2-period, 2-sequence, crossover, single dose and fasting conditions design. The test and reference formulations were administered in 2 treatment days, separated by a washout period of 7 days. Blood samples were drawn up to 96 h following drug administration. Plasma concentrations of irbesartan were obtained by a validated HPLC method using MS/MS detection. Log-transformed AUC_0–t and C_max values were tested for bioequivalence based on the ratios of the geometric LSmeans (test/reference). t_max was analysed nonparametrically. The 90% confidence intervals of the geometric LSmean values for the test/reference ratios for AUC_0–t (98.06–109.48%, point estimator 103.61%) and C_max (88.93–100.87%, point estimator 94.72%) were within the bioequivalence acceptance range of 80–125%. According to the European Guideline on the Investigation of Bioequivalence it may be therefore concluded that test formulation of irbesartan 300 mg film-coated tablet is bioequivalent to the reference formulation. Overall, it was judged that the study was conducted with a good tolerance of the subjects to both study drugs.

Key words

antihypertensive drugs - bioequivalence - CAS 138402-11-6 - irbesartan - pharmacokinetics

Full Text

References

References
1 Marino MR, Langenbacher K, Ford NF et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38: 246-255
2 Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J Hypertens Suppl 1997; 15: S15-S20
3 European Medicines Agency [Intenet]. Summary of Products Characteristics of Aprovel 300 mg film-coated tablets. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000141/WC500025752.pdf. Accessed on 22.07.2013
4 Adams MA, Trudeau L. Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol 2000; 7: 22-31
5 Vachharajani NN, Shyu WC, Mantha S et al. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol 1998; 38: 433-436
6 Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902
7 Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr, London 20 January 2010)
8 CPMP/ICH/135/95, ICH Topic E6 (R1): Guideline for Good Clinical Practice, July 2002
9 Guidance for Industry: Bioanalytical Method Validation . U.S. Department of Health and Human Services. Food and Drug Administration, May 2001;
10 Liu JP, Chow SC. Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm 1992; 20: 101-104
11 Wilcoxon F. Individual Comparisons by Ranking Methods. Biometrics Bulletin 1945; 1: 80-83
12 SAS version 9.01 software . SAS Institute Inc.; Cary, NC, USA: http://www.sas.com/
13 Marino MR, Langenbacher KM, Raymond RH et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38: 347-356